News | July 30, 2008

Study of Patients Treated Sirolimus- Versus Paclitaxel-Eluting Stents Found Little Difference

July 31, 2008 – No major difference was found in long-term safety or efficacy between sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES), according to a recent study that found both stent types were efficacious in reducing revascularization, but were limited by a small continual increase in late stent thrombosis.

The study appears in the Aug. 1 issue of the American Journal of Cardiology.

Researchers from Washington Hospital Center’s Division of Cardiology in Washington, D.C. said while multiple studies comparing SES and PES in patients with coronary artery disease have been performed, it remains uncertain whether a differential in long-term efficacy and safety exists. Unselected patients treated exclusively with one drug-eluting stent type were enrolled in the registry experience at the Washington Hospital Center. There were 2,099 patients (3,766 lesions) treated with SES and 1,079 patients (1,850 lesions) treated with PES. Patients were followed at 30 days, one year, and two years for the clinical endpoints of death, myocardial infarction, target vessel revascularization, and definite and definite/probable stent thrombosis.

Researchers said patients in the SES group had more dyslipidemia, history of congestive heart failure, and ostial lesions. The patients treated with PES had more previous coronary artery bypass surgery, unstable angina, and type C lesions.

At two years, unadjusted major adverse cardiac events (MACE) (22.6 vs. 21.1 percent, p = 0.3) and target vessel revascularization (13.3 vs. 11.2 percent, p = 0.1) were comparable. The incidence of definite stent thrombosis was higher in the SES group (1.8 vs. 0.9 percent, p = 0.05) driven by early events. Similar results were seen after adjustment for baseline differences: MACE (hazard ratio 1.1, 95 percent confidence interval [CI] 0.9 to 1.3, p = 0.5), definite stent thrombosis (hazard ratio 2.3, 95 percent CI 1.0 to 5.2, p = 0.05), and target vessel revascularization (hazard ratio 1.1, 95 percent CI 0.9 to 1.4, p = 0.4). The incidence and rate of late stent thrombosis (>30 days) were similar (0.7 vs. 0.5 percent, p = 0.4 and 0.24percent/year, both groups, respectively).

For more information: www.ajconline.org


Related Content

News | Stents

June 12, 2024 — Royal Philips, a global leader in health technology, announced the first implant of the Duo Venous Stent ...

Home June 12, 2024
Home
News | Stents

June 4, 2024 — A patient at HonorHealth Research Institute is one of the nation’s first — and the first in Arizona and ...

Home June 04, 2024
Home
News | Stents

April 17, 2024 — Getinge and Cook Medical announced an exclusive sales and distribution agreement for the iCast covered ...

Home April 17, 2024
Home
News | Stents

March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact ...

Home March 08, 2024
Home
News | Stents

January 19, 2024 — W. L. Gore & Associates, Inc. announced that the first patients have been enrolled in the Gore VBX ...

Home January 19, 2024
Home
News | Stents

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home November 29, 2023
Home
News | Stents

July 27, 2023 — Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions ...

Home July 27, 2023
Home
News | Stents

June 13, 2023 — W. L. Gore & Associates (Gore) announced the initiation of the Gore VBX FORWARD Clinical Study ...

Home June 13, 2023
Home
News | Stents

March 5, 2023 — In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents ...

Home March 05, 2023
Home
News | Stents

January 23, 2023 — A study of more than 100,000 patients has revealed that, for patients with blockages in multiple ...

Home January 23, 2023
Home
Subscribe Now